These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36854167)

  • 21. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
    Khusid JA; Weiss JP; Carlsson MO; Mangan EK
    J Urol; 2017 Nov; 198(5):1119-1123. PubMed ID: 28479240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
    Nik-Ahd F; Lenore Ackerman A; Anger J
    Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
    Mattiasson A; Masala A; Morton R; Bolodeoku J;
    BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?
    Schiavi MC; Sciuga V; Giannini A; Vena F; D'oria O; Prata G; Di Tucci C; Savone D; Aleksa N; Capone C; Di Mascio D; Meggiorini ML; Monti M; Zullo MA; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2018 Aug; 34(8):666-669. PubMed ID: 29463148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaginal erbium laser treatment for stress urinary incontinence: A multicenter randomized sham-controlled clinical trial.
    O'Reilly BA; Viereck V; Phillips C; Toozs-Hobson P; Kuhn A; Athanasiou S; Lukanović A; Palmer B; Dahly D; Daykan Y; Cardozo L
    Int J Gynaecol Obstet; 2024 Mar; 164(3):1184-1194. PubMed ID: 37927157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
    Schiavi MC; Zullo MA; Faiano P; D'Oria O; Prata G; Colagiovanni V; Giannini A; Di Tucci C; Perniola G; Di Donato V; Monti M; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2017 Dec; 33(12):942-945. PubMed ID: 28490209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
    Bunyavejchevin S
    J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraurethral Erbium:YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: A pilot study.
    Gaspar A; Maestri S; Silva J; Brandi H; Luque D; Koron N; Vižintin Z
    Lasers Surg Med; 2018 Oct; 50(8):802-807. PubMed ID: 29667744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy.
    Russo E; Misasi G; Montt-Guevara MM; Giannini A; Simoncini T
    Climacteric; 2023 Jun; 26(3):284-288. PubMed ID: 36912363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.